News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$DYAI Dyadic International: Proteins for World Health DYAI NASDAQ detailed its product portfolio, vaccines
$DYAI Buy Opinion from barchart https://www.barchart.com/stocks/quotes/DYAI/opinion
DYAI, under $2
DYAI under $2
$DYAI Dip buy opportunity -
$DYAI Traders cheat sheet https://www.barchart.com/stocks/quotes/DYAI/cheat-sheet
DYAI under $2
DYAI under $2
DYAI under $2
DYAI under $2
Dyadic International Inc. ( $DYAI ): Bird Flu Vaccine Development Amid Rising Pandemic Concerns
https://thestreetreports.com/dyadic-international-inc-dyai-bird-flu-vaccine-development-amid-rising-pandemic-concerns/
In response to this looming threat, the U.S. government has initiated discussions with Moderna (NASDAQ: MRNA) regarding an avian flu vaccine. Other companies, such as Pfizer (NYSE: PFE), Novavax (NASDAQ: NVAX), BioNTech (NASDAQ: BNTX), and Dyadic International Inc (NASDAQ: DYAI), may also be involved.
Outbreaks naturally cause concern, prompting companies to find solutions. On May 22, Australia reported its first human bird flu case, followed by a second U.S. case involving a Michigan farm worker. This surge in cases has spurred the U.S. government to engage with Moderna for vaccine development. Dyadic International Inc (NASDAQ: DYAI) is a key player to watch, given its proactive approach and promising bird flu vaccine candidate developed in collaboration with ViroVax.
Dyadic’s H5 bird flu vaccine candidate, offers significant advantages in terms of lower costs and accelerated manufacturing. Pre-clinical animal data ViroVax showed high neutralizing antibodies for three distinct H5 viruses, indicating its potential use in both cattle and humans. Scalability and flexibility are strengths of the Dyadic vaccine candidate, positioning it as a dynamic solution for a global health crisis.
The C1 production platform used by Dyadic is sustainable and cost-effective compared to MRNA and other vaccine production processes. This makes Dyadic International a crucial player in addressing the bird flu threat and ensuring preparedness for a potential outbreak.
DYAI under $3
$DYAI - "Dyadic International, Inc.’s (NASDAQ: DYAI) COO Joe Hazelton Discusses Expansion into Food and Beverage and the "Future of Foods" ..."
https://thestreetreports.com/dyadic-international-inc-s-nasdaq-dyai-coo-joe-hazelton-discusses-expansion-into-food-and-beverage-and-the-future-of-foods-on-the-street-reports-podcast-listen-now/
Dyadic International, Inc.’s (NASDAQ: DYAI) COO Joe Hazelton Discusses Expansion into Food and Beverage and the "Future of Foods" ...https://t.co/V9iubGRbEf
— Dyadic Applied BioSolutions (@DyadicInc) May 15, 2024
DYAI under $2
$DYAI
- The Street Podcast
- March 28th Financial Results & Conference Call
- Publication on Filamentous fungus-produced human monoclonal antibody
Links Below:
- https://thestreetreports.com/dyai-ceo-mark-emalfarb-shares-insights-6m-capital-raise-2024-outlook-etc-on-the-street-reports-podcast-tune-in/
- https://www.globenewswire.com/news-release/2024/03/14/2846716/0/en/Dyadic-to-Report-Full-Year-2023-Financial-Results-and-Host-Conference-call-on-Thursday-March-28-2024.html
- https://www.nature.com/articles/s41467-024-46443-0#Sec28
$DYAI CEO Mark Emalfarb Shares Insights, $6M Capital Raise, 2024 Outlook etc,. on “The Street Reports Podcast” – Tune In!
https://thestreetreports.com/dyai-ceo-mark-emalfarb-shares-insights-6m-capital-raise-2024-outlook-etc-on-the-street-reports-podcast-tune-in/
DYAI under $2
$DYAI Some of the Best Ideas from the 12th Annual Benchmark Discovery Conference
https://www.nasdaq.com/articles/some-of-the-best-ideas-from-the-12th-annual-benchmark-discovery-conference
Conference season in the investment industry may be starting to wind down, but several reputable and well-known names have just wrapped up their annual conferences. One of the most recent conferences to wrap up was the Discovery Conference, hosted by The Benchmark Company. The annual conference gives companies opportunities for one-on-one meetings with institutional investors from across the U.S. Here are some of the best ideas from this year's Discovery Conference.
Dyadic
Dyadic (DYAI) is an interesting biotechnology company working on a wide range of products for human health, animal health and alternative proteins. First, the company is applying its proprietary and patented C1 technology to develop vaccines and antibodies for infectious diseases in humans.
During the first quarter, Dyadic began dosing in a Phase 1 clinical trial of DYAI-100, a COVID-19 booster vaccine candidate based on recombinant protein. The company expects the results from this first in-human trial to accelerate the adoption of the C1-cell protein production platform.
In addition to the COVID-19 vaccine, Dyadic is also developing several other vaccines for infectious diseases, including influenza, and other illnesses, including cancer. The company is using the same C1 platform to develop vaccines and antibodies for infectious diseases in animals, with a focus on Rift-Valley fever, salmonellosis, zoonotic influenza, West Nile virus, coronavirus, plague, rabies, Lyme disease and brucellosis.
Finally, Dyadic's alternative proteins program is aimed at reducing the cost of recombinant protein production using its proprietary Dapibus platform and other technologies in the search for non-pharmaceutical recombinant proteins. As part of this last program, Dyadic has launched a strategic partnership with a global food ingredient company and is exploring licensing and product opportunities in the alternative meat industry.
Investing in high-growth sectors
All the companies on this list operate in high-growth sectors and are developing cutting-edge technologies in their fields with the potential for tremendous gains in the future. For example, one estimate pegged the quantum-computing market at $812.6 million in revenue for 2022, with a projected compound annual growth rate (CAGR) of 22% between 2023 and 2030, bringing it to $8.2 billion in revenue.
Meanwhile, another estimate suggested the blood glucose monitoring device market was worth $12.5 billion in 2022 and projected a CAGR of 8.13% between 2023 and 2030. In fact, Know Labs could eventually address many more markets than just blood glucose monitoring with its technology, so these numbers probably represent only a fraction of the company’s potential total addressable market (TAM).
Ideal Power already addresses a large number of energy-efficient markets. However, one firm estimated that EVs alone represented a $49.1 billion market in 2022 and projected a CAGR of more than 15.5% between 2023 and 2032, making it worth $215.7 billion. Thus, Ideal Power’s TAM should be significantly larger than this one market alone.
Similarly, Dyadic is working on both vaccines and antibodies for infectious diseases and other illnesses in both humans and animals. However, considering only vaccines for infectious diseases, one estimate pegs the market at $77.6 billion in 2023 with a CAGR of 3.9% between 2023 and 2028, making it worth $93.8 billion.
Of course, despite the large TAMs these companies could see, investors are always advised to do their own due diligence before investing in any company or sector.
DYAI under $2
|
Followers
|
27
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1177
|
|
Created
|
10/19/08
|
Type
|
Free
|
| Moderators | |||
AI
